Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis (Q86212403)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488486%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488486%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Socrates E Papapoulos

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488486%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

9 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488486%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Endocrinology

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488486%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488486%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488486%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

69-70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488486%20AND%20SRC:MED&resulttype=core&format=json

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.214

Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.214

Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.214

Sclerostin: current knowledge and future perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.214

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.214

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.214

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.214

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.214

Romosozumab in postmenopausal women with low bone mineral density.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.214

Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.214

31 March 2020

Identifiers

DOI

10.1038/NRENDO.2014.214

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488486%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488486%20AND%20SRC:MED&resulttype=core&format=json